Publication | Closed Access

Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target

Hematological MalignancyDisease ProgressionNew Therapeutic TargetImmunologyCell DeathImmune Checkpoint InhibitorBiological TherapyImmunotherapyMedicineCell BiologyCell SignalingNovel TherapyTumor BiologyBcl-xl Anti-apoptotic Network